Suggested remit: To appraise the clinical and cost effectiveness of pembrolizumab within its marketing authorisation for treating previously untreated HER2 negative advanced gastric or gastro-oesophageal junction adenocarcinoma.
|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
|
Reason for decision
|
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
|
| Process |
STA Standard
|
| ID number |
4030
|
Provisional Schedule
| Expected publication |
19 June 2024 |
Project Team
| Project lead |
Thomas Feist |
Email enquiries
Stakeholders
| Companies sponsors |
Merck Sharp and Dohme |
| Others |
Department of Health and Social Care |
| |
NHS England |
| Patient carer groups |
Heartburn Cancer UK |
| |
OG Support |
| Professional groups |
Association of Cancer Physicians |
| |
Cancer Research UK |
| |
Royal College of Physicians |
| |
Royal College of Radiologists |
| Comparator companies |
Bristol-Myers Squibb |
| General commentators |
All Wales Therapeutic and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Care and Services and Public Safety for Northern Ireland |
| |
Medicine and Healthcare Regulatory Agency |
| |
NHS Confederation |
| |
Scottish Medicines Consortium |
| |
Welsh Government |
| |
Welsh Health Specialised Committee |
| Relevant research groups |
Institute of Cancer Research |
|
Date
|
Update
|
|
09 April 2024
|
Committee meeting: 2 |
|
05 March 2024 - 26 March 2024
|
Draft guidance |
|
13 February 2024
|
Committee meeting: 1 |
|
11 July 2023
|
Invitation to participate |
|
17 January 2023 - 14 February 2023
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 4030 |
|
17 January 2023
|
In progress. Scoping commencing |
|
30 November 2022
|
As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Pembrolizumab with chemotherapy for treating HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma.
Please note that following on from information received from the company this appraisal has now been scheduled back into the work programme.
The appraisal is anticipated to begin during early-March 2023 when we will write to you about how you can get involved. |
|
09 November 2022
|
Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
|
09 August 2022
|
As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Pembrolizumab with chemotherapy for treating HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma.
Please note that following on from advice received from the company the timelines for this appraisal are to be confirmed. The appraisal will be rescheduled to align with latest regulatory expectations and an update on the revised timelines will be provided when further information is available. |
For further information on our processes and methods, please see our CHTE processes and methods manual